Exicure (XCUR) Stock Price, News & Analysis

Company Overview

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies.

Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area.

Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.

Key Stats

• Today's Range: $3.15 to $3.30
• 50-Day Range: $2.67 to $4.75
• 52-Week Range: $2.63 to $10.80
• Volume: 11,077 shs
• Average Volume: 25,624 shs
• Market Capitalization: $20.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Exicure Stock Analysis - MarketRank™

Exicure scored higher than 22% of companies evaluated by MarketBeat, and ranked 798th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Exicure has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Exicure has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Exicure is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exicure is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exicure has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.07% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 2.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently decreased by 38.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exicure does not currently pay a dividend.

Dividend Growth

Exicure does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.19

News Sentiment

Exicure has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Exicure this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Exicure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

52.80% of the stock of Exicure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/25/2026
• Today: 5/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XCUR
• CIK: 1698530
• Web: www.exicuretx.com
• Phone: (847) 673-1700
• Fax: N/A
• Employees: 50
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -138.71%
• Return on Assets: -62.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.19
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: $500 thousand
• Price / Sales: 40.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 5.07

Miscellaneous

• Outstanding Shares: 6,370,000
• Free Float: 3,009,000
• Market Cap: $20.01 million
• Optionable: Not Optionable
• Beta: 3.62